Answers are grounded in this paper and cite their sources.
To investigate the clinical response at week 52 in patients with ankylosing spondylitis (AS) who received secukinumab 300 vs 150 mg after inadequate response to 150 mg at week 16.
No takes yet. Share an insight, caveat, or question.
Deodhar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: